Lilly Glucagon

Phase 3Small molecule

XXeris Pharmaceuticals

Lilly Glucagon is one of 57 small molecule programs targeting Hypoglycemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

Type 1 DiabetesActive, not recruiting

HypoglycemiaPhase 3

Active, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Lilly Glucagon

XXeris Pharmaceuticals

Phase 3

1 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Pitocin

RRetrophin

Preclinical

1 6

Glargine

Eli Lilly

Preclinical

4 7

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Foradil

Viatris

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TED2 trials

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Completed·SSteven J. Russell, MD, PhD·Phase 2/3·NCT02018627·20 enrolled

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Terminated·MMassachusetts General Hospital·N/A·NCT02701257·20 enrolled

Hypoglycemia2 trials

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Completed·XXeris Pharmaceuticals·Phase 3·NCT02656069·80 enrolled

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

Completed·XXeris Pharmaceuticals·Phase 2·NCT01972152·30 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

Completed·BBiodel·Phase 1·NCT02403648·15 enrolled

Type 1 Diabetes1 trial

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Completed·XXeris Pharmaceuticals·Phase 3·NCT03439072·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Lilly Glucagon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lilly Glucagon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lilly Glucagon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xeris Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXeris Pharmaceuticals

Lilly Glucagon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TED2 trials

Hypoglycemia2 trials

Tics1 trial

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News